Aug 12, 2026 04:01PM
Jul 14, 2026 06:21AM
Jul 14, 2026 06:04AM
Jul 14, 2026 06:02AM
Jun 17, 2026 04:21PM
Jun 17, 2026 04:21PM
Jun 17, 2026 12:36PM Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
Jun 17, 2026 11:09AM
May 28, 2026 06:30AM
May 28, 2026 06:30AM
May 13, 2026 04:05PM
Mar 26, 2026 04:05PM
Dec 19, 2025 08:01AM
Dec 19, 2025 08:00AM Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
Nov 13, 2025 04:05PM
Oct 21, 2025 02:00AM
Oct 21, 2025 02:00AM
Oct 14, 2025 08:00AM
Aug 12, 2025 04:01PM
May 28, 2025 07:01AM
May 28, 2025 07:00AM Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
May 13, 2025 04:01PM
Apr 28, 2025 04:01PM
Apr 28, 2025 04:01PM
Mar 27, 2025 04:01PM
Jan 10, 2025 07:07AM
Jan 10, 2025 07:00AM
Nov 14, 2024 04:05PM Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
Oct 29, 2024 04:06PM
Oct 29, 2024 04:05PM
Oct 16, 2024 04:06PM
Oct 16, 2024 04:05PM
Oct 2, 2024 04:31PM
Oct 2, 2024 04:30PM
Aug 5, 2024 04:01PM Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update
Jul 3, 2024 01:05PM
Jun 3, 2024 04:05PM
May 16, 2024 04:05PM
May 15, 2024 04:05PM
May 8, 2024 08:00AM
May 1, 2024 04:07PM
Mar 13, 2024 04:01PM Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
Mar 6, 2024 08:05AM
Feb 28, 2024 08:05AM
Feb 28, 2024 08:05AM
Feb 26, 2024 08:05AM
Jan 31, 2024 04:05PM
Jan 5, 2024 08:05AM
Jan 5, 2024 08:05AM Spero Therapeutics Provides Corporate Update and 2024 Outlook
Jan 2, 2024 08:05AM

328,910 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All